Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections

Kazuo Sasayama, Kyoko Yamashita, Yasumasa Dotsu, Takashige Miyazaki, Hiroko Nakazato, Hideaki Shigeno, Hironobu Koga, Takashi Suyama, Masao Nagasawa, Kenji Mori, Yoshiaki Fukuda, Toshiaki Hayashi, Naomi Ito, Yoshiteru Shigeno, Keizo Yamaguchi, Masaki Hirota, Atsushi Saito, Kohei Hara, Kazuyuki Sugawara, Kazunori ShimoguchiKazunori Tomono, Nobuchika Kusano, Yasuharu Masuyama, Toshiyuki Oe, Takeshi Ishizaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Carumonam (CRMN, AMA-1080), a novel synthetic monocyclic β-lactam antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: CRMN was specifically active against aerobic Gram-negative bacteria including Pseudomonas aeruginosa. Its activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes and P. aeruginosa was in general equal or superior to that of the third-generation cephems such as ceftizoxime, cefoperazone and latamoxef. 2) Carumonam level in serum and sputum: CRMN was drip infused for 1 h to five patients with chronic respiratory infections at a dose of 1 or 2 and its serum and sputum levels were assayed microbiologically. Peak serum levels were 33.5—64.7 μg/ml with the 1 g dose and 88.4—146.6μg/ml with the 2 g dose at the end of drip infusion. Peak sputum levels were 1.21—6.56 μg/ml (2 g) at 2 to 4 h after infusion. The average ratio of peak levels in sputum to those in serum was 3.7 and 5.6%, respectively. 3) Clinical results: CRMN was administered to 13 patients with various respiratory infections. Clinical response was excellent in 2, good in 6, fair in 3 and poor in 1 patient, and 1 patient was not evaluable. The overall efficacy rate was 66.7%. In one patient S-GPT and urobilinogen values were transiently elevated mildly to moderately. We therefore conclude that CRMN is a useful antibiotics in treating patients with respiratory infections due to aerobic Gram-negative bacteria.

Original languageEnglish
Pages (from-to)450-469
Number of pages20
JournalChemotherapy
Volume35
DOIs
Publication statusPublished - 1987
Externally publishedYes

Fingerprint

Respiratory Tract Infections
Sputum
Gram-Negative Aerobic Bacteria
Serum
Pseudomonas aeruginosa
Urobilinogen
Ceftizoxime
Moxalactam
Proteus vulgaris
Anti-Bacterial Agents
Enterobacter aerogenes
Cefoperazone
Enterobacter cloacae
Lactams
Proteus mirabilis
Klebsiella pneumoniae
Intravenous Infusions
Clinical Studies
carumonam
Escherichia coli

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Sasayama, K., Yamashita, K., Dotsu, Y., Miyazaki, T., Nakazato, H., Shigeno, H., ... Ishizaki, T. (1987). Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections. Chemotherapy, 35, 450-469. https://doi.org/10.11250/chemotherapy1953.35.Supplement2_450

Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections. / Sasayama, Kazuo; Yamashita, Kyoko; Dotsu, Yasumasa; Miyazaki, Takashige; Nakazato, Hiroko; Shigeno, Hideaki; Koga, Hironobu; Suyama, Takashi; Nagasawa, Masao; Mori, Kenji; Fukuda, Yoshiaki; Hayashi, Toshiaki; Ito, Naomi; Shigeno, Yoshiteru; Yamaguchi, Keizo; Hirota, Masaki; Saito, Atsushi; Hara, Kohei; Sugawara, Kazuyuki; Shimoguchi, Kazunori; Tomono, Kazunori; Kusano, Nobuchika; Masuyama, Yasuharu; Oe, Toshiyuki; Ishizaki, Takeshi.

In: Chemotherapy, Vol. 35, 1987, p. 450-469.

Research output: Contribution to journalArticle

Sasayama, K, Yamashita, K, Dotsu, Y, Miyazaki, T, Nakazato, H, Shigeno, H, Koga, H, Suyama, T, Nagasawa, M, Mori, K, Fukuda, Y, Hayashi, T, Ito, N, Shigeno, Y, Yamaguchi, K, Hirota, M, Saito, A, Hara, K, Sugawara, K, Shimoguchi, K, Tomono, K, Kusano, N, Masuyama, Y, Oe, T & Ishizaki, T 1987, 'Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections', Chemotherapy, vol. 35, pp. 450-469. https://doi.org/10.11250/chemotherapy1953.35.Supplement2_450
Sasayama, Kazuo ; Yamashita, Kyoko ; Dotsu, Yasumasa ; Miyazaki, Takashige ; Nakazato, Hiroko ; Shigeno, Hideaki ; Koga, Hironobu ; Suyama, Takashi ; Nagasawa, Masao ; Mori, Kenji ; Fukuda, Yoshiaki ; Hayashi, Toshiaki ; Ito, Naomi ; Shigeno, Yoshiteru ; Yamaguchi, Keizo ; Hirota, Masaki ; Saito, Atsushi ; Hara, Kohei ; Sugawara, Kazuyuki ; Shimoguchi, Kazunori ; Tomono, Kazunori ; Kusano, Nobuchika ; Masuyama, Yasuharu ; Oe, Toshiyuki ; Ishizaki, Takeshi. / Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections. In: Chemotherapy. 1987 ; Vol. 35. pp. 450-469.
@article{019bff5670d345f5a73bee8793ce9140,
title = "Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections",
abstract = "Carumonam (CRMN, AMA-1080), a novel synthetic monocyclic β-lactam antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: CRMN was specifically active against aerobic Gram-negative bacteria including Pseudomonas aeruginosa. Its activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes and P. aeruginosa was in general equal or superior to that of the third-generation cephems such as ceftizoxime, cefoperazone and latamoxef. 2) Carumonam level in serum and sputum: CRMN was drip infused for 1 h to five patients with chronic respiratory infections at a dose of 1 or 2 and its serum and sputum levels were assayed microbiologically. Peak serum levels were 33.5—64.7 μg/ml with the 1 g dose and 88.4—146.6μg/ml with the 2 g dose at the end of drip infusion. Peak sputum levels were 1.21—6.56 μg/ml (2 g) at 2 to 4 h after infusion. The average ratio of peak levels in sputum to those in serum was 3.7 and 5.6{\%}, respectively. 3) Clinical results: CRMN was administered to 13 patients with various respiratory infections. Clinical response was excellent in 2, good in 6, fair in 3 and poor in 1 patient, and 1 patient was not evaluable. The overall efficacy rate was 66.7{\%}. In one patient S-GPT and urobilinogen values were transiently elevated mildly to moderately. We therefore conclude that CRMN is a useful antibiotics in treating patients with respiratory infections due to aerobic Gram-negative bacteria.",
author = "Kazuo Sasayama and Kyoko Yamashita and Yasumasa Dotsu and Takashige Miyazaki and Hiroko Nakazato and Hideaki Shigeno and Hironobu Koga and Takashi Suyama and Masao Nagasawa and Kenji Mori and Yoshiaki Fukuda and Toshiaki Hayashi and Naomi Ito and Yoshiteru Shigeno and Keizo Yamaguchi and Masaki Hirota and Atsushi Saito and Kohei Hara and Kazuyuki Sugawara and Kazunori Shimoguchi and Kazunori Tomono and Nobuchika Kusano and Yasuharu Masuyama and Toshiyuki Oe and Takeshi Ishizaki",
year = "1987",
doi = "10.11250/chemotherapy1953.35.Supplement2_450",
language = "English",
volume = "35",
pages = "450--469",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Laboratory Studies And Clinical Evaluation Of Carumonam In Respiratory Infections

AU - Sasayama, Kazuo

AU - Yamashita, Kyoko

AU - Dotsu, Yasumasa

AU - Miyazaki, Takashige

AU - Nakazato, Hiroko

AU - Shigeno, Hideaki

AU - Koga, Hironobu

AU - Suyama, Takashi

AU - Nagasawa, Masao

AU - Mori, Kenji

AU - Fukuda, Yoshiaki

AU - Hayashi, Toshiaki

AU - Ito, Naomi

AU - Shigeno, Yoshiteru

AU - Yamaguchi, Keizo

AU - Hirota, Masaki

AU - Saito, Atsushi

AU - Hara, Kohei

AU - Sugawara, Kazuyuki

AU - Shimoguchi, Kazunori

AU - Tomono, Kazunori

AU - Kusano, Nobuchika

AU - Masuyama, Yasuharu

AU - Oe, Toshiyuki

AU - Ishizaki, Takeshi

PY - 1987

Y1 - 1987

N2 - Carumonam (CRMN, AMA-1080), a novel synthetic monocyclic β-lactam antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: CRMN was specifically active against aerobic Gram-negative bacteria including Pseudomonas aeruginosa. Its activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes and P. aeruginosa was in general equal or superior to that of the third-generation cephems such as ceftizoxime, cefoperazone and latamoxef. 2) Carumonam level in serum and sputum: CRMN was drip infused for 1 h to five patients with chronic respiratory infections at a dose of 1 or 2 and its serum and sputum levels were assayed microbiologically. Peak serum levels were 33.5—64.7 μg/ml with the 1 g dose and 88.4—146.6μg/ml with the 2 g dose at the end of drip infusion. Peak sputum levels were 1.21—6.56 μg/ml (2 g) at 2 to 4 h after infusion. The average ratio of peak levels in sputum to those in serum was 3.7 and 5.6%, respectively. 3) Clinical results: CRMN was administered to 13 patients with various respiratory infections. Clinical response was excellent in 2, good in 6, fair in 3 and poor in 1 patient, and 1 patient was not evaluable. The overall efficacy rate was 66.7%. In one patient S-GPT and urobilinogen values were transiently elevated mildly to moderately. We therefore conclude that CRMN is a useful antibiotics in treating patients with respiratory infections due to aerobic Gram-negative bacteria.

AB - Carumonam (CRMN, AMA-1080), a novel synthetic monocyclic β-lactam antibiotic, was basically and clinically evaluated with the following results: 1) Antimicrobial activity: CRMN was specifically active against aerobic Gram-negative bacteria including Pseudomonas aeruginosa. Its activity against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes and P. aeruginosa was in general equal or superior to that of the third-generation cephems such as ceftizoxime, cefoperazone and latamoxef. 2) Carumonam level in serum and sputum: CRMN was drip infused for 1 h to five patients with chronic respiratory infections at a dose of 1 or 2 and its serum and sputum levels were assayed microbiologically. Peak serum levels were 33.5—64.7 μg/ml with the 1 g dose and 88.4—146.6μg/ml with the 2 g dose at the end of drip infusion. Peak sputum levels were 1.21—6.56 μg/ml (2 g) at 2 to 4 h after infusion. The average ratio of peak levels in sputum to those in serum was 3.7 and 5.6%, respectively. 3) Clinical results: CRMN was administered to 13 patients with various respiratory infections. Clinical response was excellent in 2, good in 6, fair in 3 and poor in 1 patient, and 1 patient was not evaluable. The overall efficacy rate was 66.7%. In one patient S-GPT and urobilinogen values were transiently elevated mildly to moderately. We therefore conclude that CRMN is a useful antibiotics in treating patients with respiratory infections due to aerobic Gram-negative bacteria.

UR - http://www.scopus.com/inward/record.url?scp=85007860961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007860961&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.35.Supplement2_450

DO - 10.11250/chemotherapy1953.35.Supplement2_450

M3 - Article

AN - SCOPUS:85007860961

VL - 35

SP - 450

EP - 469

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -